ID   NEMO_RAT                Reviewed;         412 AA.
AC   Q6TMG5;
DT   12-DEC-2006, integrated into UniProtKB/Swiss-Prot.
DT   05-JUL-2004, sequence version 1.
DT   02-OCT-2024, entry version 141.
DE   RecName: Full=NF-kappa-B essential modulator;
DE            Short=NEMO;
DE   AltName: Full=IkB kinase-associated protein 1;
DE            Short=IKKAP1;
DE   AltName: Full=Inhibitor of nuclear factor kappa-B kinase subunit gamma;
DE            Short=I-kappa-B kinase subunit gamma;
DE            Short=IKK-gamma;
DE            Short=IKKG;
DE            Short=IkB kinase subunit gamma;
DE   AltName: Full=NF-kappa-B essential modifier;
GN   Name=Ikbkg; Synonyms=Nemo;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Fischer 344;
RX   PubMed=12968033; DOI=10.1074/jbc.m302549200;
RA   Saito N., Courtois G., Chiba A., Yamamoto N., Nitta T., Hironaka N.,
RA   Rowe M., Yamamoto N., Yamaoka S.;
RT   "Two carboxyl-terminal activation regions of Epstein-Barr virus latent
RT   membrane protein 1 activate NF-kappaB through distinct signaling pathways
RT   in fibroblast cell lines.";
RL   J. Biol. Chem. 278:46565-46575(2003).
CC   -!- FUNCTION: Regulatory subunit of the IKK core complex which
CC       phosphorylates inhibitors of NF-kappa-B thus leading to the
CC       dissociation of the inhibitor/NF-kappa-B complex and ultimately the
CC       degradation of the inhibitor. Its binding to scaffolding polyubiquitin
CC       plays a key role in IKK activation by multiple signaling receptor
CC       pathways. Can recognize and bind both 'Lys-63'-linked and linear
CC       polyubiquitin upon cell stimulation, with a much highr affinity for
CC       linear polyubiquitin. Could be implicated in NF-kappa-B-mediated
CC       protection from cytokine toxicity. Essential for viral activation of
CC       IRF3. Involved in TLR3- and IFIH1-mediated antiviral innate response;
CC       this function requires 'Lys-27'-linked polyubiquitination.
CC       {ECO:0000250|UniProtKB:Q9Y6K9}.
CC   -!- SUBUNIT: Homodimer; disulfide-linked. Component of the I-kappa-B-kinase
CC       (IKK) core complex consisting of CHUK, IKBKB and IKBKG; probably four
CC       alpha/CHUK-beta/IKBKB dimers are associated with four gamma/IKBKG
CC       subunits. The IKK core complex seems to associate with regulatory or
CC       adapter proteins to form a IKK-signalosome holo-complex (By
CC       similarity). The IKK complex associates with TERF2IP/RAP1, leading to
CC       promote IKK-mediated phosphorylation of RELA/p65 (By similarity). Part
CC       of a complex composed of NCOA2, NCOA3, CHUK/IKKA, IKBKB, IKBKG and
CC       CREBBP. Interacts with COPS3, CYLD, NALP2, TRPC4AP and PIDD1. Interacts
CC       with ATM; the complex is exported from the nucleus. Interacts with
CC       TRAF6. Interacts with IKBKE. Interacts with TANK; the interaction is
CC       enhanced by IKBKE and TBK1. Part of a ternary complex consisting of
CC       TANK, IKBKB and IKBKG. Interacts with ZFAND5. Interacts with RIPK2.
CC       Interacts with TNIP1 and TNFAIP3; TNIP1 facilitates the TNFAIP3-
CC       mediated de-ubiquitination of IKBKG. Interacts with TNFAIP3; the
CC       interaction is induced by TNF stimulation and by polyubiquitin. Binds
CC       (via UBAN region) polyubiquitin; binds both 'Lys-63'-linked and linear
CC       polyubiquitin, with higher affinity for linear ubiquitin. Interacts
CC       with NLRP10. Interacts with TANK; this interaction increases in
CC       response to DNA damage. Interacts with USP10; this interaction
CC       increases in response to DNA damage. Interacts with ZC3H12A; this
CC       interaction increases in response to DNA damage. Interacts with IFIT5;
CC       the interaction synergizes the recruitment of IKK to MAP3K7 and
CC       enhances IKK phosphorylation. Interacts with TRIM29; this interaction
CC       induces IKBKG/NEMO ubiquitination and proteolytic degradation.
CC       Interacts with TRIM13; this interaction leads to IKBKG/NEMO
CC       ubiquitination. Interacts with ARFIP2 (By similarity). Interacts with
CC       RIPK1 (By similarity). Interacts with (ubiquitinated) BCL10;
CC       interaction with polyubiquitinated BCL10 via both 'Lys-63'-linked and
CC       linear ubiquitin is required for TCR-induced NF-kappa-B activation (By
CC       similarity). Interacts with MARCHF2; during the late stages of
CC       macrophage viral and bacterial infection; the interaction leads to
CC       ubiquitination and degradation of IKBKG/NEMO (By similarity).
CC       {ECO:0000250|UniProtKB:O88522, ECO:0000250|UniProtKB:Q9Y6K9}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q9Y6K9}. Nucleus
CC       {ECO:0000250|UniProtKB:Q9Y6K9}. Note=Sumoylated NEMO accumulates in the
CC       nucleus in response to genotoxic stress.
CC       {ECO:0000250|UniProtKB:Q9Y6K9}.
CC   -!- DOMAIN: The leucine-zipper domain and the CCHC NOA-type zinc-fingers
CC       constitute the UBAN region and are essential for polyubiquitin binding
CC       and for the activation of IRF3. {ECO:0000250|UniProtKB:Q9Y6K9}.
CC   -!- PTM: Phosphorylation at Ser-68 attenuates aminoterminal
CC       homodimerization. {ECO:0000250|UniProtKB:Q9Y6K9}.
CC   -!- PTM: Polyubiquitinated on Lys-278 via 'Lys-63'-linked ubiquitin; the
CC       ubiquitination is mediated downstream of NOD2 and RIPK2 and probably
CC       plays a role in signaling by facilitating interactions with ubiquitin
CC       domain-containing proteins and activates the NF-kappa-B pathway.
CC       Polyubiquitinated on Lys-278 and Lys-302 through 'Lys-63'-linked
CC       ubiquitin; the ubiquitination is mediated by BCL10, MALT1 and TRAF6 and
CC       probably plays a role in signaling by facilitating interactions with
CC       ubiquitin domain-containing proteins and activates the NF-kappa-B
CC       pathway. Monoubiquitinated on Lys-270 and Lys-302; promotes nuclear
CC       export. Polyubiquitinated through 'Lys-27' by TRIM23; involved in
CC       antiviral innate and inflammatory responses. Linear polyubiquitinated
CC       on Lys-111, Lys-143, Lys-226, Lys-246, Lys-270, Lys-278, Lys-285, Lys-
CC       295, Lys-302 and Lys-319; the head-to-tail polyubiquitination is
CC       mediated by the LUBAC complex and plays a key role in NF-kappa-B
CC       activation. Deubiquitinated by USP10 in a TANK-dependent and
CC       -independent manner, leading to the negative regulation of NF-kappa-B
CC       signaling upon DNA damage. Ubiquitinated at Lys-319 by MARCHF2
CC       following bacterial and viral infection which leads to its degradation.
CC       Polyubiquitinated via 'Lys-29'-linked ubiquitin; leading to lysosomal
CC       degradation. {ECO:0000250|UniProtKB:Q9Y6K9}.
CC   -!- PTM: Sumoylated on Lys-270 and Lys-302 with SUMO1; the modification
CC       results in phosphorylation of Ser-85 by ATM leading to a replacement of
CC       the sumoylation by mono-ubiquitination on these residues.
CC       {ECO:0000250|UniProtKB:Q9Y6K9}.
CC   -!- PTM: Neddylated by TRIM40, resulting in stabilization of NFKBIA and
CC       down-regulation of NF-kappa-B activity. {ECO:0000250|UniProtKB:Q9Y6K9}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY392762; AAQ94056.1; -; mRNA.
DR   RefSeq; NP_954534.1; NM_199103.1.
DR   RefSeq; XP_006229646.1; XM_006229584.3.
DR   RefSeq; XP_006229647.1; XM_006229585.3.
DR   AlphaFoldDB; Q6TMG5; -.
DR   BMRB; Q6TMG5; -.
DR   SMR; Q6TMG5; -.
DR   BioGRID; 259339; 1.
DR   CORUM; Q6TMG5; -.
DR   STRING; 10116.ENSRNOP00000075158; -.
DR   ChEMBL; CHEMBL4524001; -.
DR   PhosphoSitePlus; Q6TMG5; -.
DR   PaxDb; 10116-ENSRNOP00000053114; -.
DR   Ensembl; ENSRNOT00055040983; ENSRNOP00055033314; ENSRNOG00055023876.
DR   Ensembl; ENSRNOT00060011512; ENSRNOP00060008633; ENSRNOG00060007005.
DR   Ensembl; ENSRNOT00065025392; ENSRNOP00065019917; ENSRNOG00065015300.
DR   GeneID; 309295; -.
DR   KEGG; rno:309295; -.
DR   AGR; RGD:735223; -.
DR   CTD; 8517; -.
DR   RGD; 735223; Ikbkg.
DR   VEuPathDB; HostDB:ENSRNOG00000060936; -.
DR   eggNOG; ENOG502R4ZD; Eukaryota.
DR   HOGENOM; CLU_034097_0_0_1; -.
DR   InParanoid; Q6TMG5; -.
DR   OrthoDB; 5406882at2759; -.
DR   PhylomeDB; Q6TMG5; -.
DR   Reactome; R-RNO-1169091; Activation of NF-kappaB in B cells.
DR   Reactome; R-RNO-168638; NOD1/2 Signaling Pathway.
DR   Reactome; R-RNO-1810476; RIP-mediated NFkB activation via ZBP1.
DR   Reactome; R-RNO-202424; Downstream TCR signaling.
DR   Reactome; R-RNO-2871837; FCERI mediated NF-kB activation.
DR   Reactome; R-RNO-445989; TAK1-dependent IKK and NF-kappa-B activation.
DR   Reactome; R-RNO-450302; activated TAK1 mediates p38 MAPK activation.
DR   Reactome; R-RNO-450321; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1.
DR   Reactome; R-RNO-4755510; SUMOylation of immune response proteins.
DR   Reactome; R-RNO-5357905; Regulation of TNFR1 signaling.
DR   Reactome; R-RNO-5357956; TNFR1-induced NF-kappa-B signaling pathway.
DR   Reactome; R-RNO-5607764; CLEC7A (Dectin-1) signaling.
DR   Reactome; R-RNO-5689880; Ub-specific processing proteases.
DR   Reactome; R-RNO-5689896; Ovarian tumor domain proteases.
DR   Reactome; R-RNO-9020702; Interleukin-1 signaling.
DR   Reactome; R-RNO-933542; TRAF6 mediated NF-kB activation.
DR   Reactome; R-RNO-937039; IRAK1 recruits IKK complex.
DR   Reactome; R-RNO-937041; IKK complex recruitment mediated by RIP1.
DR   Reactome; R-RNO-975144; IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation.
DR   Reactome; R-RNO-9758274; Regulation of NF-kappa B signaling.
DR   Reactome; R-RNO-9833482; PKR-mediated signaling.
DR   Reactome; R-RNO-9860276; SLC15A4:TASL-dependent IRF5 activation.
DR   PRO; PR:Q6TMG5; -.
DR   Proteomes; UP000002494; Chromosome X.
DR   Bgee; ENSRNOG00000060936; Expressed in skeletal muscle tissue and 18 other cell types or tissues.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0005829; C:cytosol; ISO:RGD.
DR   GO; GO:0008385; C:IkappaB kinase complex; IDA:RGD.
DR   GO; GO:0072686; C:mitotic spindle; ISO:RGD.
DR   GO; GO:0005634; C:nucleus; ISO:RGD.
DR   GO; GO:0032991; C:protein-containing complex; ISO:RGD.
DR   GO; GO:0000922; C:spindle pole; ISO:RGD.
DR   GO; GO:0000151; C:ubiquitin ligase complex; ISO:RGD.
DR   GO; GO:0042802; F:identical protein binding; ISO:RGD.
DR   GO; GO:0070530; F:K63-linked polyubiquitin modification-dependent protein binding; ISS:UniProtKB.
DR   GO; GO:1990450; F:linear polyubiquitin binding; ISS:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0042975; F:peroxisome proliferator activated receptor binding; IPI:RGD.
DR   GO; GO:0031593; F:polyubiquitin modification-dependent protein binding; ISO:RGD.
DR   GO; GO:0019904; F:protein domain specific binding; ISO:RGD.
DR   GO; GO:0046982; F:protein heterodimerization activity; ISO:RGD.
DR   GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB.
DR   GO; GO:0044877; F:protein-containing complex binding; IPI:RGD.
DR   GO; GO:0035591; F:signaling adaptor activity; ISO:RGD.
DR   GO; GO:1990459; F:transferrin receptor binding; ISO:RGD.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; ISO:RGD.
DR   GO; GO:0043276; P:anoikis; ISO:RGD.
DR   GO; GO:0001782; P:B cell homeostasis; ISO:RGD.
DR   GO; GO:0007249; P:canonical NF-kappaB signal transduction; ISO:RGD.
DR   GO; GO:0042742; P:defense response to bacterium; ISO:RGD.
DR   GO; GO:0006974; P:DNA damage response; ISS:UniProtKB.
DR   GO; GO:0051650; P:establishment of vesicle localization; ISO:RGD.
DR   GO; GO:1902236; P:negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway; ISO:RGD.
DR   GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; ISS:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISO:RGD.
DR   GO; GO:0016239; P:positive regulation of macroautophagy; ISO:RGD.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; ISS:UniProtKB.
DR   GO; GO:0050862; P:positive regulation of T cell receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISS:UniProtKB.
DR   GO; GO:0065003; P:protein-containing complex assembly; ISO:RGD.
DR   Gene3D; 1.20.5.390; L1 transposable element, trimerization domain; 2.
DR   Gene3D; 1.20.5.990; Nemo cc2-lz domain - 1d5 darpin complex; 1.
DR   InterPro; IPR032419; CC2-LZ_dom.
DR   InterPro; IPR021063; NEMO_N.
DR   InterPro; IPR034735; NEMO_ZF.
DR   InterPro; IPR051301; Optineurin/NFkB_EssMod.
DR   PANTHER; PTHR31553; NF-KAPPA-B ESSENTIAL MODULATOR; 1.
DR   PANTHER; PTHR31553:SF3; NF-KAPPA-B ESSENTIAL MODULATOR; 1.
DR   Pfam; PF16516; CC2-LZ; 1.
DR   Pfam; PF11577; NEMO; 1.
DR   Pfam; PF18414; zf_C2H2_10; 1.
DR   PROSITE; PS51801; ZF_CCHC_NOA; 1.
PE   2: Evidence at transcript level;
KW   Coiled coil; Cytoplasm; Disulfide bond; DNA damage; Isopeptide bond;
KW   Metal-binding; Nucleus; Phosphoprotein; Reference proteome; Transcription;
KW   Transcription regulation; Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN           1..412
FT                   /note="NF-kappa-B essential modulator"
FT                   /id="PRO_0000269197"
FT   ZN_FING         382..412
FT                   /note="CCHC NOA-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01142"
FT   REGION          1..197
FT                   /note="Required for interaction with and ubiquitination by
FT                   MARCHF2"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   REGION          1..48
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          44..111
FT                   /note="Interaction with CHUK/IKBKB"
FT                   /evidence="ECO:0000250"
FT   REGION          150..250
FT                   /note="Interaction with TANK"
FT                   /evidence="ECO:0000250"
FT   REGION          242..343
FT                   /note="Ubiquitin-binding (UBAN)"
FT   REGION          246..358
FT                   /note="Self-association"
FT                   /evidence="ECO:0000250"
FT   REGION          249..412
FT                   /note="Required for interaction with TNFAIP3"
FT                   /evidence="ECO:0000250"
FT   REGION          315..336
FT                   /note="Leucine-zipper"
FT                   /evidence="ECO:0000255"
FT   REGION          375..412
FT                   /note="Interaction with CYLD"
FT                   /evidence="ECO:0000250"
FT   COILED          49..343
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        1..15
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         390
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01142"
FT   BINDING         393
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01142"
FT   BINDING         406
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01142"
FT   BINDING         410
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01142"
FT   MOD_RES         31
FT                   /note="Phosphoserine; by IKKB"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   MOD_RES         43
FT                   /note="Phosphoserine; by IKKB"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   MOD_RES         68
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   MOD_RES         85
FT                   /note="Phosphoserine; by ATM"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   MOD_RES         369
FT                   /note="Phosphoserine; by IKKB"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   MOD_RES         380
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   DISULFID        54
FT                   /note="Interchain"
FT                   /evidence="ECO:0000250"
FT   DISULFID        340
FT                   /note="Interchain"
FT                   /evidence="ECO:0000250"
FT   CROSSLNK        111
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   CROSSLNK        139
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   CROSSLNK        143
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   CROSSLNK        226
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   CROSSLNK        246
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   CROSSLNK        270
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO); alternate"
FT                   /evidence="ECO:0000250"
FT   CROSSLNK        270
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   CROSSLNK        276
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   CROSSLNK        278
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   CROSSLNK        285
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   CROSSLNK        295
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   CROSSLNK        302
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO); alternate"
FT                   /evidence="ECO:0000250"
FT   CROSSLNK        302
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   CROSSLNK        314
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   CROSSLNK        319
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   CROSSLNK        392
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
SQ   SEQUENCE   412 AA;  48066 MW;  6D5D96B08A4CCEC2 CRC64;
     MSRHLWKNQL SEMVQPSGGP AEDQDMLGEE SSLGKPAMLH LPSEQGTPET LQRCLEENQE
     LRDAIRQSNQ MLRERCEELL HFQVSQREEK EFLMCKFQEA RKLVERLSLE KLDLRRQREQ
     ALEDLEHLKK CQQQMAEDKA SVKAQVTSLL GELQESQSRL EAATKERQTL EGRIRAVSEQ
     VRQLESEREV LQQQHSVQVD QLRMQNQSVE AALRMERQAA SEEKRKLAQL QAAYHQLFQD
     YDSHIKSSKG MQLEDLRQQL QQAEEALVAK QELIDKLKEE AEQHKIVMET VPVLKAQADI
     YKADFQAERH AREKLVERKE LLQEQLEQLQ REFNKLKVGC HESARIEDMR KRHVETSQPP
     LLPAPAHHSF HLALSNQRRS PPEEPPDFCC PKCQYQAPDM DTLQIHVMEC IE
//
